Evercore ISI analyst Vijay Kumar upgraded Hologic (HOLX) to Outperform from In Line with a price target of $78, up from $69. Organic revenue is set-up to inflect, driven by new products and headwinds rolling off, says the analyst, who contends that topline growth should drive high-single digit EPS growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOLX:
- Hologic receives FDA clearance for Panther Fusion
- Minicarm.com named U.S. distributor of Fluoroscan Insight FD Mini C-Arm
- VolitionRx signs co-marketing and services agreement with Hologic
- Hologic’s Growth Potential: Hold Rating Amidst Uncertainties and Transient Headwinds
- Hologic Extends CEO Stephen MacMillan’s Employment Agreement